KURT SHERICK: Open Payments
NPI 1902836323 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,813 in 82 payments from 16 companies in 2025. Trend: 2023 $1,893 · 2024 $1,280 · 2025 $1,813
Food & beverage: $1,813
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $338 |
| Axsome Therapeutics, Inc. | 14 | $324 |
| E.R. Squibb & Sons, L.L.C. | 6 | $176 |
| Supernus Pharmaceuticals, Inc. | 8 | $146 |
| Lundbeck LLC | 7 | $139 |
| Teva Pharmaceuticals USA, Inc. | 7 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $106 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Janssen Pharmaceuticals, Inc | 2 | $67 |
| Corium, LLC | 3 | $66 |
Products named: CAPLYTA, Auvelity, REXULTI, COBENFY, Qelbree, UZEDY, FANAPT, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
